Cryptococcosis
13
2
2
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.7%
1 terminated out of 13 trials
87.5%
+1.0% vs benchmark
31%
4 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Fungal Infection Susceptibility
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Inpatient Package to Reduce HIV and AIDS-related Death in Zambia
Vicente Ferrer HIV Cohort Study
Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
Cryptococcal Antigen Screening Plus Sertraline
Operational Research for Cryptococcal Antigen Screening
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Vietnam Cryptococcal Retention in Care Study - Version 2.1
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection
Clinical Trial of Pulmonary Cryptococcosis in China
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections